ProCE Banner Activity

Phase IIb Trial of IRAK4 Inhibitor, PF-06650833, in Patients With Moderately to Severely Active RA and Inadequate Response to MTX

Slideset Download
Conference Coverage
PF-06650833 associated with improvements in SDAI in primary analysis.

Released: November 18, 2019

Expiration: November 16, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Mallinckrodt Pharmaceuticals